PPDI: Income Statement for Pharmaceutical Product Developm

PERIOD ENDING		30-Sep-09	30-Jun-09	31-Mar-09	31-Dec-08
Total Revenue		341,059	355,218	364,892	368,172
Cost of Revenue		175,017	183,259	188,647	182,344

Gross Profit		166,042	171,959	176,245	185,828

	Operating Expenses
	Research Development	4,605	4,701	1,526	1,323
	Selling General and Administrative	94,079	97,782	94,237	97,400
	Non Recurring	3,892	-	-	-
	Others	16,570	16,094	15,233	15,244

	Total Operating Expenses	119,146	-	-	-


Operating Income or Loss		46,896	53,382	65,249	71,861

	Income from Continuing Operations
	Total Other Income/Expenses Net	1,245	1,075	(218)	(1,915)
	Earnings Before Interest And Taxes	48,141	54,457	65,031	69,946
	Interest Expense	-	-	-	537
	Income Before Tax	48,141	54,457	65,031	69,409
	Income Tax Expense	10,468	15,793	20,733	22,210
	Minority Interest	-	-	-	-

	Net Income From Continuing Ops	37,673	38,664	44,298	47,199

	Non-recurring Events
	Discontinued Operations	-	19,397	271	-
	Extraordinary Items	-	-	-	-
	Effect Of Accounting Changes	-	-	-	-
	Other Items	-	-	-	-


Net Income		37,673	58,061	44,569	47,199
Preferred Stock And Other Adjustments		-	-	-	-

Net Income Applicable To Common Shares		$37,673	$58,061	$44,569	$47,199

Add to Portfolio

Set Alert

Email to a Friend

•	Sector Analysis

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More